国信证券发布春立医疗研报：2025年第三季度营收翻倍增长，出海业务成为第二增长曲线

Group 1 - The core viewpoint of the report is that Guosen Securities has given Chuangli Medical (688236.SH, latest price: 27.11 yuan) an "outperform" rating due to strong revenue growth and better-than-expected net profit growth [1] - The company's net profit margin has significantly improved, while the sales expense ratio has decreased substantially [1] - Chuangli Medical is expanding its product line, and its overseas business is showing impressive growth [1]